Christopher A Lamb

Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource

Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease

OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)

Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel

Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB) formalin fixed paraffin-embedded (FFPE) pancreatic tissue samples are a potential resource for microbiota analysis

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease

Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7

A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial